Dr. Remi Goupil, MD MSc
Claim this profileHôpital du Sacré-Coeur de Montréal
Studies High Blood Pressure
Studies Kidney Disease
2 reported clinical trials
2 drugs studied
Affiliated Hospitals
Clinical Trials Remi Goupil, MD MSc is currently running
Central Blood Pressure Monitoring Devices
for Chronic Kidney Disease
The most accurate way to determine intra-aortic BP is to obtain invasive measures by vascular catheterization, which is not possible to perform routinely during the regular follow-up of patients. However, in recent years, devices used to estimate central BP have been designed and approved for clinical use. These devices can determine aortic BP in a non-invasive way using various techniques and algorithms and offer a high degree of precision when compared to invasive measurements of intraaortic BP. On the other hand, certain characteristics specific to the different devices mean that the central BP values obtained may not be interchangeable. It is therefore important to determine the degree of agreement of central BP values obtained using commercially available devices. This study aims to determine the degree of agreement between central BP measurements obtained using 4 devices commonly used to measure central blood pressure, i.e. Mobil-o-Graph NG (IEM, Germany), WatchBP Office (Microlife, Taiwan), Oscar 2 with SphygmoCor inside (SunTech, USA) and BP+ (Uscom, Australia). These four devices record the shape of the pulsatile wave and then derive the central BP using an algorithm. The main differences between these devices lie in this algorithm, or "transfer function,", which is unique to each and the calibration used. All use a brachial cuff to capture the pulse waveform and can easily be used in clinical practice.
Recruiting1 award N/A1 criteria
Central vs Brachial Blood Pressure Targeting
for Chronic Kidney Disease
Background: Emerging data favors aortic blood pressure (BP) over brachial cuff BP in predicting CV and renal complications, as this BP directly impacts the heart, brain and kidneys. In parallel, central BP measuring devices have been developed that are more accurate towards aortic BP and easy to use without training. In no other condition than advanced chronic kidney disease (CKD) is BP control as important, since undertreatment is associated with adverse CV events and progression towards end-stage kidney disease (ESKD), while overtreatment similarly leads to adverse CV events and injurious falls but also acute kidney injury which can precipitate ESKD. To this day, standard BP management relies on brachial cuff BP, which is an imprecise surrogate marker of aortic BP, more so in the advanced CKD population. Considering that these patients have a high risk of CV morbidity and mortality and is a group where brachial BP may be the least reliable, it can be beneficial to manage hypertension in this population using central BP measurements. With the development of affordable and easy to use central BP devices, routine use of central BP in hypertension would now become a reality. However, the superiority of central BP to traditional brachial cuff BP in regard to clinical outcomes will first need to be demonstrated. Objectives: To demonstrate that targeting central BP in advanced CKD patients as opposed to brachial cuff BP is feasible and results in lower arterial stiffness after 12 months of follow-up. Methods: The CENTRAL-CKD trial is an investigator-initiated prospective parallel-group 1:1 randomized double-blinded multicenter pragmatic pilot trial. Patients with CKD stages 4 and 5 (n=116) will be randomized to either a central systolic BP target < 130 mmHg (intervention) or brachial systolic BP target < 130 mmHg (standard care). Central and brachial BP will be concomitantly measured, with treating physicians, patients and investigators blinded towards allocation. As this trial is of a pragmatic design, all other aspects of BP and CKD management, including anti-hypertensive treatment-related decisions, diastolic BP targets, and clinical and laboratory follow-ups will be at the discretion of the attending Nephrologist. The primary outcomes include feasibility of large-scale trial using prespecified criteria and aortic stiffness (carotid-femoral pulse wave velocity) at 12 months. Other cardiovascular, renal, quality of life and safety outcomes will be evaluated. Importance: CENTRAL-CKD is designed as a pilot trial aimed at providing the framework and justification to proceed to a large-scale trial with adequate power to detect the impact of the proposed intervention on clinically important outcomes.
Recruiting1 award N/A3 criteria
More about Remi Goupil, MD MSc
Clinical Trial Related3 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Remi Goupil, MD MSc has experience with
- Central Vs Brachial Systolic Blood Pressure Targeting
- Brachial And Central BP Measurements With Mobil-o-Graph NG Device (IEM), WatchBP Office Device (Microlife), BP+ Device (Uscom) And Oscar 2 With SphygmoCor Inside Device (SunTech)
Breakdown of trials Remi Goupil, MD MSc has run
High Blood Pressure
Kidney Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Remi Goupil, MD MSc specialize in?
Remi Goupil, MD MSc focuses on High Blood Pressure and Kidney Disease. In particular, much of their work with High Blood Pressure has involved treating patients, or patients who are undergoing treatment.
Is Remi Goupil, MD MSc currently recruiting for clinical trials?
Yes, Remi Goupil, MD MSc is currently recruiting for 2 clinical trials in Montréal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Remi Goupil, MD MSc has studied deeply?
Yes, Remi Goupil, MD MSc has studied treatments such as Central vs brachial systolic blood pressure targeting, Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech).
What is the best way to schedule an appointment with Remi Goupil, MD MSc?
Apply for one of the trials that Remi Goupil, MD MSc is conducting.
What is the office address of Remi Goupil, MD MSc?
The office of Remi Goupil, MD MSc is located at: Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec H4J1C5 Canada. This is the address for their practice at the Hôpital du Sacré-Coeur de Montréal.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.